User: Guest  Login
Title:

Efficacy and safety of palbociclib in combination with letrozole as first-line treatment of ER-positive, HER2-negative, advanced breast cancer: expanded analyses of subgroups from the randomized pivotal trial PALOMA-1/TRIO-18.

Document type:
Journal Article
Author(s):
Finn, Richard S; Crown, John P; Ettl, Johannes; Schmidt, Marcus; Bondarenko, Igor M; Láng, István; Pinter, Tamas; Boer, Katalin; Patel, Ravindranath; Randolph, Sophia; Kim, Sindy T; Huang, Xin; Schnell, Patrick; Nadanaciva, Sashi; Bartlett, Cynthia Huang; Slamon, Dennis J
Abstract:
Palbociclib is an oral small-molecule inhibitor of cyclin-dependent kinases 4 and 6. In the randomized, open-label, phase II PALOMA-1/TRIO-18 trial, palbociclib in combination with letrozole improved progression-free survival (PFS) compared with letrozole alone as first-line treatment of estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative, advanced breast cancer (20.2 months versus 10.2 months; hazard ratio (HR) = 0.488, 95 % confidence interval (CI) 0.319-...     »
Journal title abbreviation:
Breast Cancer Res
Year:
2016
Journal volume:
18
Journal issue:
1
Pages contribution:
67
Language:
eng
Fulltext / DOI:
doi:10.1186/s13058-016-0721-5
Pubmed ID:
http://view.ncbi.nlm.nih.gov/pubmed/27349747
Print-ISSN:
1465-542X
TUM Institution:
Frauenklinik und Poliklinik
 BibTeX